Form 4: Bio-Techne CFO Exercises Options, Sells Shares for Tax Obligations

Sentiment:

Insider Transaction Report 31 July 2025 4:28 PM

Bio-Techne Corporation's CFO, James Hippel, exercised stock options and subsequently sold a portion of the acquired shares to cover tax liabilities.

Summary

James Hippel, Chief Financial Officer of Bio-Techne Corp (TECH), executed transactions on July 29, 2025.
Hippel acquired 168,620 shares of common stock by exercising stock options at an exercise price of $44.33 per share.
Concurrently, 147,431 shares of common stock were disposed of at a price of $58.55 per share to satisfy tax withholding obligations related to the option exercise.
Following these transactions, James Hippel directly beneficially owns 127,799 shares of Bio-Techne common stock.
Hippel retains various unexercised stock options and unvested restricted stock units (RSUs) with different vesting schedules and performance conditions extending through 2034.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (option exercise and tax-related sale). While the sale reduces direct ownership, it's a necessary part of realizing value from equity awards. The overall sentiment is neutral to slightly positive as it reflects an executive realizing value from their compensation, which is a normal course of business.

Positives

The exercise of stock options indicates a realization of value from previously granted equity compensation.
The transaction demonstrates the CFO's continued vested interest in the company through remaining beneficial ownership and unvested equity.

Negatives

A significant portion of the acquired shares (147,431 out of 168,620) were immediately sold, primarily to cover tax liabilities, which reduces the net increase in direct ownership from the exercise.

Risks

Future Outlook

The filing does not contain forward-looking statements regarding the company's financial performance or strategic outlook, focusing solely on insider trading activities.

Industry Context

This Form 4 filing reflects routine insider transactions related to executive compensation, which are common across all industries for publicly traded companies. It does not provide insights into broader industry trends or competitive dynamics within the life sciences or biotechnology sector.

Comparison to Industry Standards

Stakeholder Impact

Shareholders: The transaction is a routine insider filing and does not indicate any significant change in company strategy or financial health. It reflects an executive monetizing part of their compensation.
Employees: No direct impact on employees beyond the reporting person.

Next Steps

Future vesting of remaining stock options and restricted stock units will occur on various dates through 2034, contingent on time-based and performance-based conditions.

Key Dates

Date	Description
08/06/2022	Vesting date for 10,134 shares of stock options with an exercise price of $120.46.
08/15/2023	Vesting date for 11,305 shares of stock options with an exercise price of $94.52.
08/06/2023	Vesting date for 10,134 shares of stock options with an exercise price of $120.46.
08/15/2024	Vesting date for 11,305 shares of stock options with an exercise price of $94.52.
08/15/2024	Vesting date for 11,481 shares of stock options with an exercise price of $84.61.
08/06/2024	Vesting date for 10,134 shares of stock options with an exercise price of $120.46.
07/29/2025	Date of earliest transaction, involving the exercise of stock options and sale of common stock.
08/06/2025	Vesting date for 10,134 shares of stock options with an exercise price of $120.46.
08/08/2025	Expiration date for 168,620 stock options with an exercise price of $44.33, which were fully exercised.
08/15/2025	Vesting date for 11,305 shares of stock options with an exercise price of $94.52.
08/15/2025	Vesting date for 11,481 shares of stock options with an exercise price of $84.61.
08/15/2025	Vesting date for 8,104 shares of stock options with an exercise price of $74.91.
08/15/2025	Vesting date for 4,010 restricted stock units.
08/15/2025	Vesting date for 10,912 performance restricted stock units and 33,916 performance stock options if certain performance goals are achieved.
11/01/2025	Vesting date for 13,159 restricted stock units.
11/01/2025	Vesting date for 11,545 restricted stock units.
08/07/2026	Expiration date for 186,068 stock options with an exercise price of $47.60.
08/15/2026	Vesting date for 11,305 shares of stock options with an exercise price of $94.52.
08/15/2026	Vesting date for 11,480 shares of stock options with an exercise price of $84.61.
08/15/2026	Vesting date for 8,104 shares of stock options with an exercise price of $74.91.
08/15/2026	Vesting date for 4,010 restricted stock units.
08/15/2026	Vesting date for 13,865 performance restricted stock units and 37,314 performance stock options if certain performance goals are achieved.
11/01/2026	Vesting date for 11,545 restricted stock units.
08/05/2027	Expiration date for 167,328 stock options with an exercise price of $66.97.
08/15/2027	Vesting date for 11,481 shares of stock options with an exercise price of $84.61.
08/15/2027	Vesting date for 8,104 shares of stock options with an exercise price of $74.91.
08/15/2027	Vesting date for 4,011 restricted stock units.
08/15/2027	Vesting date for 24,062 performance restricted stock units if certain performance goals are achieved.
11/01/2027	Vesting date for 11,544 restricted stock units.
08/06/2028	Expiration date for 40,536 stock options with an exercise price of $120.46.
08/15/2028	Vesting date for 8,105 shares of stock options with an exercise price of $74.91.
08/15/2029	Expiration date for 33,916 performance stock options with an exercise price of $94.52.
08/15/2029	Expiration date for 45,220 stock options with an exercise price of $94.52.
08/15/2030	Expiration date for 37,314 performance stock options with an exercise price of $84.61.
08/15/2030	Expiration date for 45,923 stock options with an exercise price of $84.61.
08/15/2034	Expiration date for 32,417 stock options with an exercise price of $74.91.

Recommendation

hold

This Form 4 filing details a routine insider transaction (option exercise and sale for tax purposes) by the CFO. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a normal part of executive compensation and does not signal a significant positive or negative outlook for the company's stock price.

Keywords

Bio-Techne, TECH, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, CFO, Executive Compensation, Share Sale, Tax Withholding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.